![conference banner](/images/conference-banner.jpeg)
Abstract
Embelin is a natural product, inhibitor of XIAP (X-chromosome-linked Inhibitor of APoptosis) with strong proapoptotic properties on cancer cells. In order to clarify the role of two OH groups on benzoquinone core, we have prepared by hemisynthesis close analogs of embelin, where these OH groups have been replaced in a systematic manner by OMe and OAc groups. Proapoptotic activities of six embelin derivatives have been studied as single agent, or in combination with TRAIL, and their abilities to interact with XIAP have been evaluated by Surface Plasmon Biacore. Our results show that these new embelin analogs have good proapoptotic properties against selected cancer cells, often higher than the natural product itself. Further, this activity is not directly mediated by XIAP. Altogether these preliminary results demonstrate that for active embelin analogs, the two OH groups are not absolutely required for anticancer activity, opening new possibilities for the design of proapoptotic derivatives in these series.
Keywords: Apoptosis, Cancer, Embelin, Hemisynthesis, Natural Products, XIAP.
Medicinal Chemistry
Title:Hemisynthesis of Selected Embelin Analogs and Investigation of their Proapoptotic Activity Against Cancer Cells
Volume: 9 Issue: 8
Author(s): Guillaume Viault, Katragadda Suresh Babu, Fabien Gautier, Sophie Barillé-Nion, Philippe Juin, Olivier Tasseau and René Grée
Affiliation:
Keywords: Apoptosis, Cancer, Embelin, Hemisynthesis, Natural Products, XIAP.
Abstract: Embelin is a natural product, inhibitor of XIAP (X-chromosome-linked Inhibitor of APoptosis) with strong proapoptotic properties on cancer cells. In order to clarify the role of two OH groups on benzoquinone core, we have prepared by hemisynthesis close analogs of embelin, where these OH groups have been replaced in a systematic manner by OMe and OAc groups. Proapoptotic activities of six embelin derivatives have been studied as single agent, or in combination with TRAIL, and their abilities to interact with XIAP have been evaluated by Surface Plasmon Biacore. Our results show that these new embelin analogs have good proapoptotic properties against selected cancer cells, often higher than the natural product itself. Further, this activity is not directly mediated by XIAP. Altogether these preliminary results demonstrate that for active embelin analogs, the two OH groups are not absolutely required for anticancer activity, opening new possibilities for the design of proapoptotic derivatives in these series.
Export Options
About this article
Cite this article as:
Viault Guillaume, Babu Suresh Katragadda, Gautier Fabien, Barillé-Nion Sophie, Juin Philippe, Tasseau Olivier and Grée René, Hemisynthesis of Selected Embelin Analogs and Investigation of their Proapoptotic Activity Against Cancer Cells, Medicinal Chemistry 2013; 9 (8) . https://dx.doi.org/10.2174/1573406411309080003
DOI https://dx.doi.org/10.2174/1573406411309080003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Current Pharmaceutical Design The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Patent Selections
Recent Patents on Nanomedicine PCM1: A Potential Prognostic Biomarker Correlated with Immune Infiltration in Lung Adenocarcinoma
Current Proteomics New Era on Combining Both Imaging and Drug Delivery to Treat Cancer
Current Pharmaceutical Biotechnology Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews Modulation of Poly(A)-specific Ribonuclease (PARN): Current Knowledge and Perspectives
Current Medicinal Chemistry Potent Phosphatidylinositol 3-Kinase Inhibitors and Their Biology
Current Drug Discovery Technologies The Heterogeneity of Glioma Stem Cells
Current Signal Transduction Therapy <i>In-situ</i> Gels for Brain Delivery: Breaching the Barriers
Current Pharmaceutical Design Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets